Access Restriction

Author Mutti, Luciano ♦ Gaudino, Giovanni
Source Directory of Open Access Journals (DOAJ)
Content type Text
Publisher PAGEPress Publications
File Format HTM / HTML
Date Created 2013-04-08
Copyright Year ©2011
Language English
Subject Domain (in LCC) RZ201-999 ♦ RC31-1245
Subject Keyword Other systems of medicine ♦ Internal medicine ♦ Medicine ♦ Ranpirnase - Mesothelioma - Ribonucleases
Abstract Ribonucleases are a superfamily of RNA-cleaving enzymes that can be cytotoxic since the cleavage of RNA makes its information indecipherable. Ranpirnase is a novel ribonuclease which preferentially degrades tRNA, thus leading to an inhibition of protein synthesis and, ultimately, to cytostasis and cytotoxicity. Ranpirnase has demonstrated antitumor activity both in vitro and in vivo in several tumor models, including malignant mesothelioma. A large phase II trial showed that ranpirnase has diseasemodifying activity against mesothelioma. A first phase III study demonstrated that rampirnase may be combined with doxorubicin and that such an association is more active than Ranpirnase alone against mesothelioma. At present, another large, phase III trial in combination with doxorubicin has completed enrollment and its results are awaited. In all the above studies, ranpirnase died not demonstrate conventional anticancer activity, stabilizing progressive disease and potentially prolonging patients’ survival. Finally, a better understanding of its mechanism of action, coupled with its favorable toxicity profile, especially characterized by the lack of major hematologic toxicities, makes ranpirnase an attractive drug to test in combination with other anticancer agents, in MMe as well as in other tumor types.
ISSN 19705565
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG ♦ Career/Technical Study
Learning Resource Type Article
Publisher Date 2011-12-01
e-ISSN 19705565
Journal Oncology Reviews
Volume Number 2
Issue Number 1

Source: Directory of Open Access Journals (DOAJ)